Zelluna ASA – Contemplates private placement

Core Viewpoint - Zelluna ASA is planning a private placement of NOK 50-55 million and a retail offering to fund the initiation of a Phase I clinical trial for its TCR-NK therapy, ZI-MA4-1, aimed at treating cancer, with patient data expected by mid-2026 [1] Private Placement Details - The private placement will issue new shares at an offer price of NOK 10 per share, with a total gross proceeds target of NOK 50-55 million [3][5] - Existing shareholders have pre-committed to subscribe for NOK 50.7 million in shares [2] - The bookbuilding period for the private placement starts on 3 November 2025 and ends on 4 November 2025 [4] Use of Proceeds - Net proceeds from the private placement and retail offering will be allocated to initiate the Phase I clinical trial, develop the pipeline, and cover general corporate purposes [2] Retail Offering - The retail offering, through PrimaryBid, aims to raise up to the NOK equivalent of EUR 1 million, targeting retail investors in Norway [1][16] - The application period for the PrimaryBid Offering is from 3 November 2025 at 16:30 (CET) to 3 November 2025 at 21:00 (CET) [21] Settlement and Allocation - Settlement for the private placement is expected to occur in two tranches, with Tranche 1 anticipated around 6 November 2025 [8][9] - The allocation of shares will be determined by the Board in consultation with the Manager after the application period ends [20] Company Overview - Zelluna ASA focuses on developing "off-the-shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies for advanced solid cancers, aiming to provide safe and cost-effective treatments globally [24]